WASHINGTON, Feb. 20 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases.
The notice was published in the Federal Register on Feb. 20 by Alycia Booth, NIH Federal Register Certifying Official, National Institutes of Health.
Summary: The Department of Health and Human Services, National Institutes of Health published a Notice in the Federal Registeron August 5, 2025. That notice requires a correction in the SUPPLEMENTARY INFORMATIONsection.
The full text of the notice can be found at: http://www.gpo.gov/fdsys/pkg/FR-2026-02-20/html/2026-0333...